Study details
Enrolling now
Defibrotide for Sickle Cell Disease Patients Undergoing Stem Cell Transplant
New York Medical College
NCT IDNCT02675959ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 11 years
Ages
0.5–34
Locations
4 sites in CA, FL, NY +1
About this study
This trial is testing the safety and effectiveness of giving Defibrotide to adults and children with sickle cell disease who are undergoing a stem cell transplant. The goal is to see if this treatment helps prevent or treat sinusoidal obstructive syndrome (SOS), a serious complication after the transplant.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Defibrotide
PhasePhase 2
DrugDefibrotide
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
defibrotide